Search

Objectives: Little is known about the use of antidementia medications in Australia. Other countries have reported sociodemographic disparities in use. Our objective was to estimate prevalence, duration, and time to initiation of antidementia medication (cholinesterase inhibitors or memantine) among Australians with dementia in residential aged care facilities and to evaluate resident and facility factors associated with use.Methods: Dynamic retrospective cohort study of people with dementia in 68 residential aged care facilities during 2014 to 2017 using electronic health record and medication administration data. Regression evaluated relationships between medication use (prevalence, duration, and time to initiation) and resident and facility characteristics.Results: Five thousand three hundred fifty-four residents with dementia were included in the analyses. Annual prevalence of antidementia medication use was less than 10% each year and decreased during the study period by 2-percentage points by 2017 (relative to 2014). Antidementia medication use varied by sociodemographic characteristics (3-points lower for single, 4-points lower for divorced relative to married residents, and 3-points higher for Australian-born). Each point in ADL score was associated with 0.1-point lower medication use. Antidementia medication use was lower in outer regional facilities. Most comorbidities were associated with lower antidementia medication use (myocardial infarction, cerebrovascular disease and heart failure 3-points lower, respiratory disease, and diabetes 2-points lower). Age had a complex relationship with antidementia medication use that varied by sex and if medication was started before or after admission. After admission, males initiated antidementia medication earlier than females.Conclusions: Antidementia medication use in Australian facilities was lower than in other countries and varied by clinical and sociodemographic factors. [ABSTRACT FROM AUTHOR]

To measure comprehensive medical assessment (CMA) completions among aged care residents in Australia; and to report the outcomes of a CMA service trial. A population-based descriptive study of CMA completions using Medicare data; and a qualitative study of an intervention trial carried out at a 115-bed residential aged care facility in Sydney, Australia. Fifty residents participated in the trial; 15 interviews were conducted. In 2008, less than 50% of Australian aged care residents had a CMA completed. The CMA service trial improved CMA data quality and accessibility. A substantial proportion of residents were found to have previously unidentified health problems that impacted on their health and quality of life. CMA rates are low. New approaches to achieving higher CMA rates, utilising information technology, hold promise. Strategies for ongoing monitoring of care to follow-up problems identified are required to achieve measurable improvements in residents' care and quality of life. [ABSTRACT FROM AUTHOR]